Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CNS

- PMLiVE

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Plans to file for approval in US and Europe in early 2020

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Regeneron reveals first data for bispecific antibody in multiple myeloma

Could be a pivotal treatment for patients who have exhausted options

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

- PMLiVE

FDA clears Alnylam’s second RNAi drug for rare disease

Second drug in the class to be cleared by regulatory authority

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

- PMLiVE

Regeneron scores positive data in phase 3 cholesterol trial

Targets severe inherited disorder

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

- PMLiVE

ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players

- PMLiVE

Alnylam gains key NICE approval for Onpattro

Important milestone for company's first product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links